miCure
Therapeutics

Pioneering microRNA solutions for the central nervous system

About

Originally founded in 2013 with technology spun out of the Weizmann Institute of Science, miCure leverages its deep understanding of the role of microRNAs in the biology of psychiatric diseases. More recently, the company has expanded its scientific and technological scope to include neurodegenerative and neurologic diseases, as well as other classes of RNAi therapeutics and novel methods to deliver oligonucleotides to the CNS.

Lead Program

A novel microRNA approach for 
treatment-resistant depression
micurerx_Iconos_azul-04

Based on miR-135

mir-135 is a key modulator of depression and anxiety in numerous animal models

micurerx_Iconos_azul-02

Selective

No reduction of post-synaptic HTR1A

micurerx_Iconos_azul-03

Biologic effect

Serotonin brain levels increase

micurerx_Iconos_azul-06

Technology

Non-invasive brain delivery

micurerx_Iconos_azul-01

Dual activity

Modulates both Serotonin transporter and HTR1a auto receptor

micurerx_Iconos_azul-05

Precision medicine

Ability to target specific neurons in the dorsal raphe nucleus

micurerx_Iconos_azul-07

High profile

Immunologically safe

Technology

Proprietary non-invasive oligonucleotide brain delivery technology. It allows precise delivery of siRNA, miRNA and ASOs to modulate gene expression in specific cells.
The technology consists of linking the oligonucleotide of interest to a small molecule ligand that binds to neurotransmitter transporters or GPCR receptors.
Pre-clinical data in rodent and non-human primate models, including proof-of-concept studies showing viability of intranasal (“nose-to-brain”) administration of oligonucleotide conjugates

Phone

+34663885719

Email Address

info@micurerx.com

Address

Amot Investment Tower, 2 Weizmann St., 24th Floor Tel-Aviv 6423902 , Israel

Contact

Write Us and we'll get back to you